[PD-1/PD-L1 Signaling Pathway and Its Anti-Tumor Effect in Lymphoma -Review]

Area of Science:

• Immunology
• Oncology

Background:

• Programmed cell death-1 (PD-1) inhibits T-cell activation, aiding tumor immune escape.
• PD-1 and its ligand PD-L1 are implicated in lymphoma development.
• This pathway represents a potential therapeutic target for lymphoma.

Purpose of the Study:

• To review the mechanism of the PD-1/PD-L1 signaling pathway.
• To summarize PD-1 and PD-L1 expression in lymphoma.
• To discuss the anti-tumor effects of PD-1/PD-L1 antibodies in lymphoma.

Main Methods:

• Literature review of PD-1/PD-L1 signaling in cancer.
• Analysis of PD-1 and PD-L1 expression in lymphoma studies.
• Summary of clinical trial data for PD-1/PD-L1 inhibitors in lymphoma.

Main Results:

• PD-1/PD-L1 signaling promotes lymphoma immune evasion.
• High PD-L1 expression is observed on lymphoma cells, with PD-1 up-regulation in tumor-infiltrating lymphocytes.
• Monoclonal antibodies targeting PD-1/PD-L1 restore T-cell function and inhibit tumor growth.

Conclusions:

• The PD-1/PD-L1 pathway is a critical factor in lymphoma pathogenesis.
• Blocking this pathway with antibodies is a promising strategy for lymphoma treatment.
• Early clinical trials indicate significant efficacy and favorable safety profiles for these agents in recurrent lymphoma.